MEDVU
DEAD

Serial Number

87117832

Owner

SIGHTLINE INNOVATION INC.

Attorney

Jorie L. Stroup

Filing Date

Jul 27, 2016

Add to watchlist:

No watchlists yet
View on USPTO

MEDVU Trademark

Serial Number: 87117832

MEDVU is a trademark filed by SIGHTLINE INNOVATION INC. on July 27, 2016. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

SIGHTLINE INNOVATION INC. (9 trademarks)

Suite 209
Toronto, ONTARIO M6H3A7 , CA

Entity Type: 03

Trademark Details

Filing Date

July 27, 2016

Registration Date

Not Registered

Published for Opposition

July 11, 2017

Goods & Services

Computer software for use in medical diagnostics, medical image analysis, medical screening, medical testing, DNA screening for medical purposes, and genetic testing for medical purposes; computer software for the analysis of medical data, namely, medical imaging data, health care data, health records, medical records, genomic data, and environmental factors, for use in the prevention, diagnosis and treatment of medical conditions, analyzing clinical trials, analyzing drug interactions, development of vaccines and medicines, medical diagnostics, molecular medicine, precision medicine, and structural and functional analysis of genomes; computer software for use in the detection, identification, analysis, and classification of pathogens and toxins in a biological sample; computer software for the analysis of genomic data for use in tracking variation and mutation of pathogens; computer software featuring machine learning and deep learning algorithms for use in medical diagnostic testing, medical image analysis, medical screening, medical testing, DNA screening for medical purposes, genetic testing for medical purposes, detection of pathogens and toxins in a biological sample, and molecular medicine, namely research, diagnosis and treatment of medical conditions on the basis of molecular mechanisms of disease; computer software for determining and predicting patterns in data, namely, medical data, genomic data, proteomic data, metabolomics data, transcriptomic data, nutritional and nutrigenomics data, medical imaging data, health care data, health records, medical records, genomic data, and environmental factor data; computer software for executing preconfigured non-field specific machine learning and deep learning algorithms and processes for the purposes of uploading and managing data for the training of preconfigured data models implemented on a hosted software platform utilizing said machine learning and deep learning processes and for utilizing said trained data models for determining and predicting patterns in said data

Medical diagnostic services in the fields of infectious diseases, rheumatological diseases, cardiovascular diseases, respiratory diseases, endocrine diseases, neurological diseases, nephrological diseases, urological diseases, gynaecological diseases, obstetrical diseases, hematological diseases, gastroenterological diseases, neuropsychiatry, and oncology; Medical screening; Medical testing services in the fields of infectious diseases, rheumatological diseases, cardiovascular diseases, respiratory diseases, endocrine diseases, neurological diseases, nephrological diseases, urological diseases, gynaecological diseases, obstetrical diseases, hematological diseases, gastroenterological diseases, neuropsychiatry, and oncology; DNA screening for medical purposes; genetic testing for medical purposes

Structural and functional analysis of genomes; research and development of vaccines and medicines; development of pharmaceutical preparations and medicines; providing software as a service (SaaS) for enabling others to access software for use in medical diagnostics, medical image analysis, medical screening, medical testing, DNA screening for medical purposes, and genetic testing for medical purposes; providing software as a service (SaaS) for enabling others to access software for the analysis of medical data, namely, medical imaging data, health care data, health records, medical records, genomic data, and environmental factors, for use in the prevention, diagnosis and treatment of medical conditions, analyzing clinical trials, analyzing drug interactions, development of vaccines and medicines, medical diagnostics, molecular medicine, namely research, diagnosis and treatment of medical conditions on the basis of molecular mechanisms of disease, precision medicine, namely the customization and personalization of therapies and medical treatment practices for individual patients, and structural and functional analysis of genomes; providing software as a service (SaaS) for enabling others to access software for use in the detection, identification, analysis, and classification of pathogens and toxins in a biological sample; providing software as a service (SaaS) for enabling others to access software for the analysis of genomic data for use in tracking variation and mutation of pathogens; providing software as a service (SaaS) for enabling others to access and use machine learning and deep learning algorithms for use in medical diagnostics, medical image analysis, medical screening, medical testing, DNA screening for medical purposes, genetic testing for medical purposes, detection of pathogens and toxins in a biological sample, and molecular medicine, namely research, diagnosis and treatment of medical conditions on the basis of molecular mechanisms of disease; providing software as a service (SaaS) for enabling others to upload and manage data for determining and predicting patterns in the data, namely, medical data, genomic data, proteomic data, metabolomics data, transcriptomic data, nutritional and nutrigenomics data, medical imaging data, health care data, health records, medical records, genomic data, and environmental factors; providing software as a service (SaaS) for enabling others to upload and manage data for the training of data models by machine learning and deep learning processes

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Apr 8, 2019 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Apr 8, 2019 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 7, 2018 EXRA
SOU EXTENSION 2 GRANTED
Sep 5, 2018 EX2G
SOU EXTENSION 2 FILED
Sep 5, 2018 EXT2
SOU TEAS EXTENSION RECEIVED
Sep 5, 2018 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 1, 2018 EXRA
SOU EXTENSION 1 GRANTED
Feb 27, 2018 EX1G
SOU EXTENSION 1 FILED
Feb 27, 2018 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 27, 2018 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 5, 2017 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 11, 2017 NPUB
PUBLISHED FOR OPPOSITION
Jul 11, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 21, 2017 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 30, 2017 CNSA
EXAMINER'S AMENDMENT ENTERED
May 26, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 26, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
May 26, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 26, 2017 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 9, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 9, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 9, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 9, 2016 GNRN
NON-FINAL ACTION E-MAILED
Nov 9, 2016 GNRT
NON-FINAL ACTION WRITTEN
Nov 9, 2016 CNRT
ASSIGNED TO EXAMINER
Nov 7, 2016 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 1, 2016 NWOS
NEW APPLICATION ENTERED
Jul 30, 2016 NWAP